key: cord-1024272-0m7kkbqd
authors: Shu, Ting; Ning, Wanshan; Wu, Di; Xu, Jiqian; Han, Qiangqiang; Huang, Muhan; Zou, Xiaojing; Yang, Qingyu; Yuan, Yang; Bie, Yuanyuan; Pan, Shangwen; Mu, Jingfang; Han, Yang; Yang, Xiaobo; Zhou, Hong; Li, Ruiting; Ren, Yujie; Chen, Xi; Yao, Shanglong; Qiu, Yang; Zhang, Ding-Yu; Xue, Yu; Shang, You; Zhou, Xi
title: Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19
date: 2020-10-20
journal: Immunity
DOI: 10.1016/j.immuni.2020.10.008
sha: 3fa9d837813bfc293979d863196a70b3433e67d4
doc_id: 1024272
cord_uid: 0m7kkbqd

The COVID-19 pandemic is a global public health crisis. However, little is known about the pathogenesis and biomarkers of COVID-19. Herein, we profiled host responses to COVID-19 by performing plasma proteomics of a cohort of COVID-19 patients including non-survivors and survivors recovered from mild or severe symptoms, and uncovered numerous COVID-19-associated alterations of plasma proteins. We developed a machine learning-based pipeline to identify 11 proteins as biomarkers and a set of biomarker combinations, which were validated by an independent cohort and accurately distinguished and predicted COVID-19 outcomes. Some of the biomarkers were further validated by ELISA using a larger cohort. These markedly altered proteins, including the biomarkers mediate pathophysiological pathways such as immune or inflammatory responses, platelet degranulation and coagulation, and metabolism, that likely contribute to the pathogenesis. Our findings provide valuable knowledge about COVID-19 biomarkers, and shed light on the pathogenesis and potential therapeutic targets of COVID-19.

conditions. In addition, although most COVID-19 patients only show mild symptoms, 7 S3), with an average number of proteins ranged from 460.4 to 676.6 ( Fig. 2B and 138 S1C). For Cohort 1, lower numbers of peptides and proteins were identified in MT1, 139 MT2 and H against other samples ( Fig. 2A-B) , probably due to batch effect. 140 To evaluate the reliability of the proteomic data in Cohort 1, we checked the raw 141 MS/MS data and found that 6705 peptides (79.1%) could be matched by ≥ 2 spectral 142 counts (Fig. 2C) . The average spectral counts were calculated as 19.4 for all peptides, 143 indicating the proteomic results are highly reliable at the peptide level. Also, we found 144 that 472 proteins (54.8%) could be traced and supported by ≥ 2 peptides, with an 145 average number of 10.0 peptides (Fig. 2D) . Thus, our quantification results are also 146 highly reliable at the protein level. The distribution of proteins identified in different 147 samples was analyzed, and we found that up to 348 (40.4%) proteins were 148 simultaneously quantified in all the 62 samples (Fig. 2E) , indicating a high 149 reproducibility of the proteomic profiling for Cohort 1. 150 To ensure the data quality, only 530 proteins mutually quantified in > 70% 151 samples (≥ 44) were reserved for Cohort 1. For each protein, multivariate normal 152 imputation (MVNI) was applied to impute the missing values (Lee and Carlin, 2010) . 153 The (Fig. S1E) , or the 530 proteins 156 after imputation (Fig. S1F ). Before normalization, it was found that the batch 5, 6 and indicating the batch effect was greatly reduced (Fig. S1E ). The imputation did not 160 influence the separation of different types of samples by normalization (Fig. S1F) . 161 The F and S samples were not completely separated (Fig. S1E-F 190 We found that two processes, platelet degranulation and the complement and 191 coagulation cascades, obtained the highest enrichment ratio (E-ratio) scores in the GO 192 and KEGG analyses, respectively ( Fig. 3A-B) . Also, the proteins involved in these 193 two processes were more dramatically altered in FT1-FT4 and ST1 compared to those Table   198 S6). These findings imply that the dysfunction of platelet degranulation and 199 coagulation cascades are closely related with the severity of COVID-19. 200 In addition to host proteins, we also identified two SARS-CoV-2-encoded 201 proteins, nsP2 and nsP7, in the plasma samples of S (5 out of 7 S patients) and F 202 groups (2 out of 5 F patients), respectively, while neither of them could be found in value of the combination of the three protein plus age is 1 (Fig. S4I ), same as that 268 without considering age as a factor (Fig. 5D ). Thus, age is a factor but not a decisive Table S6 ). 296 Besides these elevated plasma proteins, we also found the levels of FETUB, 297 CETP, and PI16 were significantly reduced in more severe conditions ( Table S8 . Plasma 313 samples from these patients were collected and then subjected to ELISA analyses for 314 detecting the plasma levels of ORM1, AZGP1, CFI, FETUB and S100A8/S100A9, 315 respectively. Of note, S100A9 and its partner S100A8, which was also detected in our 316 study, function as a heterodimer that can be detected together. The ELISA results 317 showed that the plasma levels of ORM1, S100A8/S100A9, AZGP1 and CFI were 318 significantly elevated in more severe COVID-19 conditions, while the level of 319 FETUB was significantly reduced in more severe ones ( Figure 6C -G and Table S8 ), 320 which are consistent with our proteomic findings. (Table S9 , P < 0.05, adjusted P < 0.05). One exception was S100A9 with a 328 non-significant value (P = 0.108, adjusted P = 0.113) in distinguishing F and S 329 samples, although the combination of CETP, S100A9 and CRP achieved a promising 330 accuracy to predict severe COVID-19 patients with or without fatal outcome. 331 In summary, these results further confirmed the accuracy of our proteomic data, 332 and more importantly, validated that the biomarkers identified in this study have 333 promising potentials to clinically monitor and evaluate the progression of COVID-19. inflammation. In addition, the S100A8/S100A9 complex is a danger-associated 388 molecular pattern (DAMP) that promotes inflammation, and its extracellular functions 389 include neutrophil and leukocyte recruitment, proinflammatory cytokine release, and 390 apoptotic induction (Wang et al., 2018). Given that plasma S100A8 and S100A9 were 391 significantly elevated in more severe COVID-19 and the S100A8/S100A9 inhibitors, Table S5 and S10. 564 To ensure the data quality and maximally use the proteomic data, proteins 565 quantified in < 70% samples of Cohort 1 were discarded. 

Welch's t-test (Table S5 ). The statistical analyses were conducted by the ttest_ind 584 function in scipy.stats. The multiple testing correction was not performed. In the last step, the 5-fold cross-validation was conducted for model training, 646 parameter optimization and performance evaluation. For each candidate combination, 647 we randomly generated a training data set and a testing data set with a ratio of 648 approximately 4:1. The testing data set was only used to evaluate the performance but Figure 1 and See also Figure S1 and Table S2- See also Figure S3 and Table S2 and S7. 

Use of a 710 surface plasmon resonance method to investigate antibiotic and plasma protein interactions

COVID-19 cytokine storm: the interplay between inflammation and 763 coagulation

KEGG: new 765 perspectives on genomes, pathways, diseases and drugs

Mammalian plasma fetuin-B is a selective inhibitor of 768 ovastacin and meprin metalloproteinases

IID 2018 update: context-specific physical 770 protein-protein interactions in human, model organisms and domesticated species

The story of complement factor I

Multiple imputation for missing data: fully conditional specification 774 versus multivariate normal imputation

A scored human protein-protein interaction network to 777 catalyze genomic interpretation

Zinc-alpha2-Glycoprotein Is Associated with Obesity in Chinese People and HFD-Induced Obese Mice

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus 783 origins and receptor binding

Orosomucoid, an acute response protein with 785 multiple modulating activities

787 iProX: an integrated proteome resource

Plasma metabolomic and lipidomic alterations associated with COVID-19

A new coronavirus associated with human respiratory disease in China

Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a 859 multicenter retrospective study from Wuhan, China

Thrombocytopenia and its 864 association with mortality in patients with COVID-19

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a 867 single-centered, retrospective, observational study. The Lancet Respiratory Medicine

Abundant proteins in 869 platelet-rich fibrin and their potential contribution to wound healing: An explorative proteomics study 870 and review of the literature

Liver injury in COVID-19: management and challenges

Proteomic Profiling of Purified 874 Rabies Virus Particles

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan

 904 We thank the patients, and the nurses and clinical staffs who are providing care 905 for these patients. We also thank many staff members at Wuhan Jinyintan Hospital 906 and SpecAlly Life Technology Co., Ltd. for their contributions and assistance in this 907 study, and Dr. Zhimei Ma for technical support. We thank Mr. An Wang and other 908 members of Zhou group for their assistance. We sincerely pay tribute to our